Novartis was the first pharmaceutical company with a global leadership position in both patented prescription and generic pharmaceuticals.
Sandoz plays a critical role in the Novartis strategy of offering a complete range of treatment options to patients, physicians and healthcare providers worldwide. This broad portfolio helps to make affordable, high-quality medicines available to patients world-wide and helps stabilize healthcare systems around the world as governments face increasing cost containment pressures.
Two main elements empower the Sandoz business strategy:
- Global reach and reputation: In addition to its unique position within Novartis, Sandoz benefits from a strong global presence and powerful brand recognition worldwide.
- Unique expertise: Sandoz distinguishes itself primarily through its ability to develop, produce and commercialize differentiated medicines. Sandoz is the pioneer and global leader of biosimilars — follow-on versions of biopharmaceuticals following loss of patent protection — with the first three approved and marketed products in the EU (human growth hormone Omnitrope, anemia medicine Binocrit, and oncology medicine Zarzio).
Sandoz - adding value through key differentiated pillars
Sandoz differentiates itself through its ability to develop, produce and commercialize complex, value-added products. The company specializes in complex, differentiated products with a focus on biosimilars, as well as generic injectables, inhalables, ophthalmics, dermatology medicines, anti-infectives and other difficult-to-make generics.
For additional information please roll-over the Sandoz graphic below.
High-quality, clinically-proven alternatives to existing biologics that offer comparable safety and efficacy at a more affordable price. Sandoz pioneered and is the clear #1 in the combined regions of North America, Europe, Japan and Australia, with each of its three marketed biosimilars the leading biosimilar in their respective markets.
Non-biologic drugs taken via injection, which include affordable, state-of-the-art generic medicines. Sandoz has been the global leader in terms of sales in injectables since 2011.
High-quality medicines that target the anatomy, physiology and diseases of the eye. With the addition of Falcon's broad line of generic ophthalmic and optic products, Sandoz is now the global generics leader in this differentiated field.
In this challenging regulatory environment, complex drugs are combined with sophisticated delivery devices to meet a rapidly growing demand for affordable new options to treat asthma and COPD (chronic obstructive pulmonary disease). With a rich pipeline, Sandoz holds a strong global #5 position in this area. Over time it aims to achieve a leadership position to complement its leadership positions in the other strategic areas.
Strong generic dermatology development and manufacturing expertise, particularly in the area of semi-solid forms such as creams and ointments, as well as a well-known branded business, PharmaDerm, which markets over 60 FDA-approved topical therapies in the US. Since the acquisition of Fougera Pharmaceuticals , Sandoz is the #1 global company in generic dermatologicals.
Sandoz holds the #1 position in the market in this area and is a fully-integrated provider of affordable, high-quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms.